Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia
- 1 August 2017
- journal article
- review article
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 31 (4) , 577-587
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Molecular pathology of tumor‐initiating cells: Lessons from Philadelphia chromosome‐positive leukemiaPathology International, 2011
- The Biology of Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- Bcr/Abl expression stimulates integrin function in hematopoietic cell lines.Journal of Clinical Investigation, 1996
- Abl tyrosine kinase in signal transduction and cell-cycle regulationCurrent Opinion in Genetics & Development, 1993
- Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.Proceedings of the National Academy of Sciences, 1990
- Acute leukaemia in bcr/abl transgenic miceNature, 1990
- Induction of Chronic Myelogenous Leukemia in Mice by the P210
bcr/abl
Gene of the Philadelphia ChromosomeScience, 1990
- In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome.Proceedings of the National Academy of Sciences, 1987
- A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa StainingNature, 1973